Blood Pressure Medication Recall Expands Over Wrong Expiration Dates and Dissolution Failures

• by Shimanta Das
• October 1, 2026

If you take blood pressure medication—or know someone who does—there’s a new recall you’ll want to know about. Inventia Healthcare first recalled certain lots of chlorthalidone tablets, used to treat high blood pressure, back in June. Then, on September 3, the company initiated a separate recall involving an additional lot of the medication. More than 25,000 bottles have now been recalled in the United States due to “failed dissolution specifications”—which can impact the effectiveness of the drug, according to the FDA. The agency has classified both recalls as Class II, meaning the product may cause temporary or medically reversible health consequences, but the probability of serious harm is remote.

The latter reason is primarily why expiration dates on medications exist—mainly because their potency can weaken between when they’re made and when they’re administered to the patient. That’s an important point in a newly updated recall on blood pressure medication due to the wrong expiration date being listed. An incorrect expiration date could lead patients to take medication that has lost potency, potentially reducing its ability to control blood pressure. Chlorthalidone is a diuretic commonly prescribed to treat hypertension, and consistent effectiveness is crucial for managing the condition.

Stopping blood pressure medication suddenly can itself create health risks, making medical guidance especially important. Patients who have recalled tablets should not stop taking their medication without consulting a healthcare professional. Instead, they should check whether their specific lot number is affected and contact their pharmacist or doctor for replacement or alternative options. The FDA encourages patients to report any adverse effects or quality issues through its MedWatch program.

This recall serves as a reminder of the importance of medication quality and the role of regulatory oversight. As the situation develops, patients are advised to stay informed through official FDA announcements and to follow their healthcare provider’s advice. For now, the recall remains a Class II event, and no serious injuries have been reported in connection with the affected lots.